Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.

Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate (ADC) linking a semi-synthetic derivative of calicheamicin, a DNA damage-inducing agent, to a humanized monoclonal antibody specific for CD33. Sixteen (55%) patients had ELN favorable-risk AML (5 [31%] by cytogenetics and 11 [69%] by genotype), 6 (21%) patients had ELN intermediate-risk AML, and 7 (24%) patients had ELN adverse-risk AML (4 [57%] by cytogenetics and 3 [43%] by genotype). In current practice, however, routine use of GO outside of the context of patients with core-binding factor (CBF) AML is relatively limited, despite 97% of patients in the ALFA-0701 study having non-CBF AML [[5], [12]]. Currently, 7 + 3 + GO is included in the recommendations of the National Comprehensive Cancer Network (NCCN) for treatment induction in AML patients <60 years old with either favorable-risk cytogenetics ("preferred"), or with intermediate- or poor-risk disease excluding patients with therapy-related AML, AML with myelodysplasia-related changes (AML-MRC), or AML with FLT3 mutations [[11]]. [Extracted from the article]